NMDA receptor antagonists inhibit apomorphine-induced climbing behavior not only in intact mice but also in reserpine-treated mice

Behavioural Brain Research

Volumn 100, Issue 1-2, 1999, Pages 135-142

  Kim, Hack Seang ^a   Rhee, Gyu Seek ^b   Oh, Seikwan ^c   Park, Woo Kyu ^d  

^a Chungbuk National University   (South Korea)

^b Korea Food and Drug Administration   (South Korea)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

AP 5; Apomorphine; Climbing behavior; CPP; Dextromethorphan; Dextrorphan; Ketamine; MK 801; NMDA

Indexed keywords

APOMORPHINE; DEXTROMETHORPHAN; DEXTRORPHAN; DIZOCILPINE; DOPAMINE RECEPTOR; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RESERPINE;

ANIMAL EXPERIMENT; ARTICLE; CLIMBING; DOPAMINE BRAIN LEVEL; LOCOMOTION; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOMORPHINE; BRAIN; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; NEURAL INHIBITION; RECEPTORS, DOPAMINE; RECEPTORS, N-METHYL-D-ASPARTATE; RESERPINE; STEREOTYPED BEHAVIOR;

EID: 0032997627     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(98)00122-3     Document Type: Article

References (64)

1. Albin R.L., Makowiec R.L., Hollingsworth Z.R., Dure L.S., Penney J.B., Young A.B. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience. 46:1992;35-48.
2. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
3. Baldessarini R.J., Kula N.S., Walton K.G., Borgman R.J. Behavioral effects of apomorphine and diisobutyrylapomorphine in the mouse. Psychopharmacology. 53:1977;45-53.
4. Bouyer J.J., Park D.H., Joh T.H., Pickel V.M. Chemical and structural analysis of the relation between cortical inputs and tyrosine hydroxylase-containing terminals in rat neostriatum. Brain Res. 302:1984;267-276.
5. Carlsson A. Neurocircuitries and neurotransmitter interactions in schizophrenia. Int Clin Psychopharmacol. 10:1995;21-28.
6. Carlsson M., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm. 75:1989;221-226.
7. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and parkinson's disease. Trends Neurosci. 13:1990;272-276.
8. Carlsson M., Svensson A. The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA 494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice. Life Sci. 47:1990;1729-1736.
9. Carter C.J., L'Heureux R., Scatton B. Differential control by N-methyl-D-aspartate and kainate of striatal dopamine release in vivo: a trans-striatal dialysis study. J Neurochem. 51:1988;462-468.
10. Clineschmidt B.V., Martin G.E., Bunting P.R., Papp M.L. Central sympathomimetic activity of (+)-5-methyl-10-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic and apparent anxiolytic properties. Drug Dev Res. 2:1982;135-145.
11. Clow D.W., Jhmandas K. Characterization of L-glutamate action on the release of endogenous dopamine from the rat caudate-putamen. J Pharmacol Exp Ther. 248:1989;722-728.
12. Costall B., Naylor R.J., Nohria V. Climbing behavior induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur J Pharmacol. 50:1978;39-50.
13. Costentin J., Protais P., Schwartz J.C. Rapid and dissociated changes in sensitivities of different dopamine receptors in mouse brain. Nature. 257:1975;405-407.
14. Dimpfel W., Spuler M. Dizocilpine (MK-801), ketamine and phencyclidine: low doses affect brain field potentials in the freely moving rat in the same way as activation of dopaminergic transmission. Psychopharmacology. 101:1990;317-323.
15. 2 receptors. Eur J Pharmacol. 255:1994;203-213.
16. Freed W.J., Cannon-Spoor H.E. A possible role of AA2 excitatory amino acid receptors in the expression of stimulant drug effects. Psychopharmacology. 101:1990;456-464.
17. Freund T.F., Powell J.F., Smith A.D. Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience. 13:1984;1189-1216.
18. Gancher S., Mayer A. Sensitization to apomorphine-induced rotational behavior in 6-OHDA-lesioned rats: effects of NMDA antagonists on drug response. Brain Res. 682:1995;63-68.
19. Gianutsos G., Palmeri J.L. Effects of three dopamine agonists on cage climbing behavior. Psychopharmacology. 79:1983;329-331.
20. Giorguieff M.F., Kemel M.L., Glowinski J. Presynaptic effect of L-glutamic acid on the release of dopamine in rat striatal slices. Neurosci Lett. 6:1977;73-77.
21. 2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK-801. J Neural Transm. 4:1992;15-26.
22. Greenamyre J.T. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neural Transm. 91:1993;255-269.
23. Greenamyre J.T., Young A.B. Synaptic localization of striatal NMDA, quisqualate and kainate receptors. Neurosci Lett. 101:1989;133-137.
24. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol. 12:1957;12-15.
25. Hamilton M.H., De Belleroche J.S., Gardiner I.M., Herberg L.J. Stimulatory effect of N-methyl-D-aspartate on locomotor activity and transmitter release from rat nucleus accumbens. Pharmacol Biochem Behav. 25:1986;943-948.
26. Heimer L., Switzer R.D., Van Hoesen G.W. Ventral striatum and ventral pallidum: components of the motor system? Trends Neurosci. 5:1982;83-87.
27. Hoffman D.C. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm. 89:1992;1-10.
28. Imperato A., Scrocco M.G., Bacchi S., Angelucci L. NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur J Pharmacol. 187:1990;555-556.
29. Karler R., Calder L.D., Thai L.H., Bedingfield J.B. A dopaminergic-glutamatergic basis for the action of amphetamine and cocaine. Brain Res. 658:1994;8-14.
30. Kashihara K., Hamamura T., Okumura K., Otsuki S. Effect of MK-801 on endogenous dopamine release in vivo. Brain Res. 528:1990;80-82.
31. Kaur S., Starr M. Motor effects of lanotrigine in naive and dopamine-depleted mice. Eur J Pharmacol. 304:1996;1-6.
32. Kelley A.E., Throne L.C. NMDA receptors mediate the behavioral effect of amphetamine infused into the nucleus accumbens. Brain Res Bull. 29:1992;247-254.
33. Kim H.S., Rhee G.S., Jung J.Y., Lee J.H., Jang C.G., Park W.K. Inhibition by noncompetitive NMDA receptor antagonists of apomorphine-induced climbing behavior in mice. Life Sci. 58:1996;1397-1402.
34. Kuribara H., Asami T., Ida I., Tadokoro S. Characteristics of the ambulation-increasing effect of the noncompetitive NMDA antagonist MK-801 in mice: Assessment by the coadministration with central-acting drugs. Jpn J Pharmacol. 58:1992;11-18.
35. Lapin I.P., Rogawski M.A. Effects of D1 and D2 dopamine receptor antagonists and catecholamine depleting agents on the locomotor stimulation induced by dizocilpine in mice. Behav Brain Res. 70:1995;145-551.
36. Loscher W., Annies A., Honack D. The NMDA receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci Lett. 198:1991;191-194.
37. Loscher W., Honack D. The novel competitive N-methyl-D-aspartate (NMDA) antagonist CGP 37849 preferentially induces phencyclidine-like behavioral effects in kindled rats: attenuation by manipulation of dopamine, alpha-1 and serotonin 1A receptors. J Pharmacol Exp Ther. 257:1991;1146-1153.
38. Martin P., Svensson A., Carlsson A., Carlsson M.L. On the roles of D-1 vs. D-2 receptors for the hyperactivity response elicited by MK-801. J Neural Transm. 95:1994;113-121.
39. Mele A., Castellano C., Felici A., Cabib S., Caccia S., Oliverio A. Dopamine-N-methyl-D-aspartate interactions in the modulation of locomotor activity and memory consolidation in mice. Eur J Pharmacol. 308:1996;1-12.
40. Moghaddam B., Gruen R.J. Do endogenous excitatory amino acids influence striatal dopamine release? Brain Res. 544:1991;329-330.
41. Moghaddam B., Guen R.J., Roth R.H., Bunny B.S., Adams R.N. Effect of L-glutamate on the release of striatal dopamine: in vivo dialysis and electrochemical studies. Brain Res. 518:1990;55-60.
42. Nieoullon A., Cheramy A., Glowinski J. Release of dopamine evoked by electrical stimulation of the motor and visual areas of the cerebral cortex in both caudate nuclei and in substantia nigra in the cat. Brain Res. 145:1978;69-84.
43. Ouagazzal A., Nieoullon A., Amalric M. Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in rats. Psychopharmacology. 11:1993;427-434.
44. Ouagazzal A., Nieoullon A., Amalric M. Locomotor activation induced by MK-801 in the rat: postsynaptic interactions with dopamine receptors in the ventral striatum. Eur J Pharmacol. 251:1994;229-236.
45. Protais P., Costentin J., Schwartz J.C. Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptor in striatum. Psychopharmacology. 50:1976;1-6.
46. Pulvirenti L., Swerdlow N.R., Koob G.F. Microinjection of a glutamate antagonist into the nucleus accumbens reduces psychostimulant locomotion in rats. Neurosci Lett. 103:1989;213-218.
47. Quagazzal A., Nieoullon A., Amalric M. Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in rats. Psychopharmacology. 111:1993;427-434.
48. Raffa R.B., Ortegon M.E., Robisch D.M., Martin G.E. In vivo demonstration of enhancement of MK-801 by glutamate. Life Sci. 44:1989;1593-1599.
49. Ramoa A.S., Alkondon M., Aracava Y., Irons J., Lunt G.G., Deshpande S.S., Wonnacott S., Aronstam R.S., Albuquerque E.X. The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels. J Pharmacol Exp Ther. 254:1990;71-82.
50. Rao T.S., Kim H.S., Lehmann J., Martinand L.L., Wood P.L. Selective activation of dopaminergic pathways in the mesocortex by compounds that act at the phencyclidine (PCP) binding site: tentative evidence for PCP recognition sites not coupled to N-methyl-D-aspartate (NMDA) receptor. Neuropharmacology. 29:1990;225-230.
51. 3H]dopamine from rat striatum: an in vivo model for glutamate actions. J Neurochem. 32:1979;1539-1545.
52. Rubinstein M., Gershanik O., Stefano F.J.E. Different roles of D1 and D2 dopamine receptors involved in locomotor activity of supersensitive mice. Eur J Pharmacol. 148:1988;419-426.
53. Rubinstein M., Muschietti J.P., Gershanik O., Flawia M.M., Stefano F.J.E. Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice. J Pharmacol Exp Ther. 252:1990;810-816.
54. Shimizu N., Duan S., Hori T., Oomura Y. Glutamate modulates dopamine release in the striatum as measured by brain microdialysis. Brain Res Bull. 25:1990;99-102.
55. Smith A.D., Bolam J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurons. Trends Neurosci. 13:1990;259-265.
56. Somogyi P., Bolam J.P., Smith A.D. Monosynaptic cortical input and local axon collaterals of identified striatonigral neurons: a light and electron microscopic study using the Golgi-peroxidase transport-degeneration procedure. J Comp Neurol. 195:1981;567-584.
57. Starr M.S., Starr B.S. Glutamate antagonists modify the motor stimulant actions of D1 and D2 agonists in reserpine-treated mice in complex ways that are not predictive of their interactions with the mixed D1/D2 agonist apomorphine. J Neural Transm. 6:1993;215-226.
58. Starr M.S., Starr B.S. Facilitation of dopamine D1 receptor - but no dopamine D1/D2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse. Eur J Pharmacol. 250:1993;239-246.
59. Starr B.S., Starr M.S., Kilpatrick I.C. Behavioral role of dopamine D1 receptors in the reserpine-treated mouse. Neuroscience. 22:1987;179-188.
60. Svensson A., Carlsson A., Carlsson M.L. Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice. J Neural Transm. 90:1992;199-217.
61. Svesson A., Carlsson M.L., Carlsson A. Interaction between glutamatergic and dopaminergic tone in the nucleus accumbens of mice: evidence for a dual glutamatergic function with respect to psychomotor control. J Neural Transm. 88:1992;235-240.
62. Svesson A., Carlsson M.L., Carlsson A. Glutamatergic neurons projecting to the nucleus accumbens can affect motor functions in opposite directions depending on the dopaminergic tone. Prog Neuropsychopharmacol Biol Psychiatry. 18:1994;1203-1218.
63. Totterdell S., Smith A.D. Convergence of hippocampal and DAergic input onto identified neurons in the nucleus accumbens of the rat. J Chem Neuroanat. 2:1989;285-298.
64. Von Voigtlander P.F., Losey E.G., Triezenberg H.J. Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment. J Pharmacol Exp Ther. 193:1975;88-94.